Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
基本信息
- 批准号:7590055
- 负责人:
- 金额:$ 34.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-02-01 至 2014-01-31
- 项目状态:已结题
- 来源:
- 关键词:AbscessAntibiotic ResistanceAntibiotic TherapyAreaBiological AssayBlocking AntibodiesCell Adhesion MoleculesCellsChemotaxisCutaneousDataDefectDendritic CellsDevelopmentFamily memberFutureGenerationsGranulopoiesisHost DefenseHost Defense MechanismHumanImaging TechniquesImaging technologyImmuneImmune responseImmune systemIn VitroIncidenceInfectionInfectious Skin DiseasesInterleukin-1Interleukin-12Interleukin-17InterventionLangerhans cellMediatingMediator of activation proteinModalityModelingMulti-Drug ResistanceMusNeutrophil InfiltrationPathway interactionsPopulationPredispositionPreventionProductionPublic HealthPublishingReceptor ActivationResearchRoleSignal TransductionSiteSkinStaphylococcus aureusSyringesSystemT-LymphocyteTLR2 geneTestingTherapeuticThickTimeToll-like receptorsTranslatingVirulentbasechemokinecombatcytokineeffective therapyhuman diseasein vivoin vivo Modelinnovationinsightinterleukin-23keratinocytemacrophagemast cellmethicillin resistant Staphylococcus aureusmouse modelneutrophilnovelnovel therapeuticspathogenpublic health relevanceresearch studyresistant strainresponsetherapeutic targetyellow-1
项目摘要
DESCRIPTION (provided by applicant): Staphylococcus aureus skin infections have emerged as a major public health threat in the U.S. as a result the dramatic increase in incidence and the ongoing emergence of methicillin-resistant S. aureus (MRSA) and multi-drug resistant strains. This application will focus on investigating mechanisms of neutrophil recruitment and host defense against S. aureus skin infections and using the information gained from understanding these pathways to develop innovative therapeutic strategies. Based on our published findings and preliminary data, we hypothesize that a major pathway by which the innate immune system combats S. aureus skin infections involves pathogen recognition by Toll-like receptors (TLRs), secretion of IL-1 followed by induction of IL-23/IL-17, which subsequently triggers neutrophil recruitment to the skin. We further hypothesize that different components of this pathway can serve as therapeutic targets against S. aureus skin infections. To test these hypotheses, an in vivo mouse cutaneous S. aureus skin infection model in combination with in vivo imaging techniques to track both the neutrophil recruitment and bacterial clearance in real-time will be used. In addition, innovative human skin culture systems, including cultures of specific innate immune cell populations derived directly from human skin, organotypic keratinocytes, and full thickness human skin explants in combination with human neutrophil chemotaxis assays will be used to determine the predominant cytokines and chemokines that promote neutrophil recruitment in the context of S. aureus infection. Lastly, novel therapeutic strategies will be developed that target human resident skin innate immune cell populations to enhance production of those mediators found to be important in triggering neutrophil recruitment. This application will provide important new insights into mechanisms of neutrophil recruitment and host defense S. aureus skin infections. Furthermore, this study has significant translational potential, since the development of innovative therapeutic strategies to engage the host's neutrophilic response will provide the groundwork for future prevention and treatment interventions against S. aureus skin infection. We believe that this application is timely and relevant, since the need for new and effective treatment modalities are desperately needed to help combat these infections, which are becoming increasingly resistant to antibiotic therapy.
PUBLIC HEALTH RELEVANCE. Staphylococcus aureus skin infections represent a major public health threat in the U.S. as a result of the dramatic increased incidence of these infections and the widespread emergence of virulent and antibiotic- resistant strains. The ultimate objective of this application is to uncover novel insights into mechanisms of host defense against S. aureus skin infection and to use these insights to develop innovative immune-based therapeutic strategies that will provide the groundwork for future prevention and treatment interventions against S. aureus skin infections. We believe that this area of research is highly significant, since the need for new and effective treatment modalities are desperately needed to help combat these infections, which are becoming increasingly resistant to antibiotic therapy.
描述(由申请人提供):金黄色葡萄球菌的皮肤感染已成为美国的主要公共卫生威胁,因此,发病率的急剧增加以及持续耐甲氧西林的金黄色葡萄球菌(MRSA)(MRSA)和多耐用耐药菌的持续出现。该应用将着重研究中性粒细胞募集的机制和针对金黄色葡萄球菌感染的宿主防御,并利用从了解这些途径中获得的信息来开发创新的治疗策略。根据我们发表的发现和初步数据,我们假设先天免疫系统对抗金黄色葡萄球菌皮肤感染的主要途径涉及Toll样受体(TLRS)的病原体识别IL-1,然后诱导IL-23/IL-17,然后诱导IL-23/IL-17,随后触发了中性幼体的招募。我们进一步假设该途径的不同组成部分可以作为针对金黄色葡萄球菌感染的治疗靶标。为了检验这些假设,将使用体内皮肤链球菌皮肤感染模型以及体内成像技术,以实时跟踪中性粒细胞募集和细菌清除率。 In addition, innovative human skin culture systems, including cultures of specific innate immune cell populations derived directly from human skin, organotypic keratinocytes, and full thickness human skin explants in combination with human neutrophil chemotaxis assays will be used to determine the predominant cytokines and chemokines that promote neutrophil recruitment in the context of S. aureus infection.最后,将开发出新的治疗策略,以靶向人类居民皮肤先天免疫细胞群体,以增强那些在触发嗜中性粒细胞募集中很重要的介体的产生。该应用将为中性粒细胞募集机制和宿主防御金黄色葡萄球菌皮肤感染提供重要的新见解。此外,这项研究具有巨大的转化潜力,因为开发了吸引宿主的嗜中性粒细胞反应的创新治疗策略将为未来预防和针对金黄色葡萄球菌皮肤感染的治疗干预措施提供基础。我们认为,这种应用是及时且相关的,因为迫切需要对新的有效治疗方式的需求来帮助应对这些感染,这些感染变得越来越对抗生素疗法具有抗药性。
公共卫生相关性。金黄色葡萄球菌皮肤感染代表了美国的主要公共卫生威胁,这是由于这些感染的发病率急剧增加以及耐药和抗生素耐药菌菌株的广泛出现。该应用的最终目标是发现对宿主防御链球菌皮肤感染的机制的新颖见解,并使用这些见解来开发创新的基于免疫的治疗策略,这些策略将为未来的预防和治疗干预措施针对金黄色葡萄球菌皮肤感染提供基础。我们认为,这一研究领域非常重要,因为迫切需要需要新的有效治疗方式来帮助打击这些感染,这些感染变得越来越抗抗生素治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lloyd S Miller其他文献
Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model
从化脓性汗腺炎异种移植小鼠模型的开发中吸取的经验教训
- DOI:
- 发表时间:
2019 - 期刊:
- 影响因子:0
- 作者:
Q. Q. Quartey;Robert J. Miller;B. Pinsker;U. J. Okoh;William D Shipman;Beth A George;Chibuikem Nwizu;L. Barnes;M. Kerns;J. Caffrey;O. Aliu;Isabelle D. Brown;Farah Succaria;J. Maynard;Amber S Herbert;Sewon Kang;Lloyd S Miller;G. Okoye;A. Byrd - 通讯作者:
A. Byrd
Lloyd S Miller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lloyd S Miller', 18)}}的其他基金
Human in vivo Th17 cell responses in cutaneous immunity to Staphylococcus aureus
人体内 Th17 细胞对金黄色葡萄球菌皮肤免疫的反应
- 批准号:
9196957 - 财政年份:2016
- 资助金额:
$ 34.65万 - 项目类别:
STAT3-mediated immunity to Staphylococcus aureus in skin
STAT3介导的皮肤金黄色葡萄球菌免疫
- 批准号:
9055474 - 财政年份:2016
- 资助金额:
$ 34.65万 - 项目类别:
STAT3 and IL-17-Th17 in skin immunity to MRSA
STAT3 和 IL-17-Th17 在皮肤对 MRSA 的免疫中的作用
- 批准号:
8903440 - 财政年份:2014
- 资助金额:
$ 34.65万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
8012861 - 财政年份:2009
- 资助金额:
$ 34.65万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
8417741 - 财政年份:2009
- 资助金额:
$ 34.65万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
8213386 - 财政年份:2009
- 资助金额:
$ 34.65万 - 项目类别:
Innate Immune Response to Staphylococcus aureus in Skin
对皮肤金黄色葡萄球菌的先天免疫反应
- 批准号:
7761267 - 财政年份:2009
- 资助金额:
$ 34.65万 - 项目类别:
Host defense against Staphylococcus aureus skin infections
宿主防御金黄色葡萄球菌皮肤感染
- 批准号:
7513375 - 财政年份:2008
- 资助金额:
$ 34.65万 - 项目类别:
Host defense against Staphylococcus aureus skin infections
宿主防御金黄色葡萄球菌皮肤感染
- 批准号:
7651292 - 财政年份:2008
- 资助金额:
$ 34.65万 - 项目类别:
Host defense against Staphylococcus aureus skin infections
宿主防御金黄色葡萄球菌皮肤感染
- 批准号:
7799065 - 财政年份:2008
- 资助金额:
$ 34.65万 - 项目类别:
相似国自然基金
基于高通量测序和培养组学的伴侣动物-人抗生素抗性基因分布特征及传播研究
- 批准号:82373646
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
手性酰胺类农药污染的农业土壤中抗生素抗性基因传播扩散的对映选择性机制
- 批准号:42377238
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
猪粪水热炭对红壤-蔬菜系统中抗生素抗性基因的风险控制及其机理
- 批准号:42307038
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
蚯蚓-菌根协同消减抗生素抗性基因的微生物驱动机制
- 批准号:32301448
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
生物炭对厌氧膜生物反应器抑制畜禽养殖废水中抗生素抗性基因的调控作用和机制
- 批准号:52300210
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Dual-Wavelength Blue Light Irradiation for Improved Treatment of Staphylococcus aureus Infections
双波长蓝光照射改善金黄色葡萄球菌感染的治疗
- 批准号:
10724476 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Photodynamic therapy for perforated appendicitis
光动力疗法治疗穿孔性阑尾炎
- 批准号:
10722767 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Development of DksA-targeted Antibiotics for Treatment of Gram-negative Infections
开发用于治疗革兰氏阴性菌感染的 DksA 靶向抗生素
- 批准号:
10487785 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Impact of mucin fermenting microbes on the virulence of Pseudomonas aeruginosa in chronic rhinosinusitis
粘蛋白发酵微生物对慢性鼻窦炎铜绿假单胞菌毒力的影响
- 批准号:
10430744 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Focused Ultrasound Treatment of Skin and Soft Tissue Abscesses
皮肤和软组织脓肿的聚焦超声治疗
- 批准号:
10339133 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别: